<?xml version="1.0" encoding="UTF-8"?>
<p>Next, we investigated the effect of 25HC on virus fusion with target cells. To simulate viral envelope fusion with plasma membrane, we performed cell–cell fusion studies by ectopically expressing SARS‐CoV‐2 S in EtOH‐ or 25HC‐treated 293FT cells (Figs 
 <xref rid="embj2020106057-fig-0002" ref-type="fig">2</xref>F and 
 <xref rid="embj2020106057-fig-0002ev" ref-type="fig">EV2</xref>G) and Vero E6 cells (Fig 
 <xref rid="embj2020106057-fig-0002ev" ref-type="fig">EV2</xref>H) with EGFP to visualize spike‐induced syncytia (Belouzard 
 <italic>et al</italic>, 
 <xref rid="embj2020106057-bib-0002" ref-type="ref">2009</xref>). EtOH‐treated cells, but not 25HC‐treated cells, formed large multinucleate syncytia upon SARS‐CoV‐2 S expression (Figs 
 <xref rid="embj2020106057-fig-0002" ref-type="fig">2</xref>F and 
 <xref rid="embj2020106057-fig-0002ev" ref-type="fig">EV2</xref>H). Since 25HC demonstrates broad anti‐human coronavirus activity, we asked whether 25HC could inhibit SARS‐CoV‐S‐mediated and MERS‐CoV‐S‐mediated cell–cell fusion. Similar to SARS‐CoV‐2 S, ectopic expression of SARS‐CoV‐S and MERS‐CoV‐S in EtOH‐treated, but not 25HC‐treated cells, induced the formation of large syncytia (Figs 
 <xref rid="embj2020106057-fig-0002" ref-type="fig">2</xref>G and 
 <xref rid="embj2020106057-fig-0002ev" ref-type="fig">EV2</xref>I). These results strongly support a function for 25HC in blocking human coronavirus spike‐mediated fusion with the plasma membrane, thereby suppressing virus entry.
</p>
